The siRNA-mediated knockdown of AP-1 restores the function of the pulmonary artery and the right ventricle by reducing perivascular and interstitial fibrosis and key molecular players in cardiopulmonary disease

Table 2 Echocardiographic assessments for the three hamster groups: C, MCT, MCT-siRNA AP-1

Echocardiographic parameters	C group (n = 5)	MCT group (n = 5)	MCT-siRNA AP-1 group (n = 5)
VTI (mm)	44.21 ± 3.4	48.95 ± 7.90	51.22 ± 9.47
Vel (mm/s)	− 1045.61 ± 40.19	− 1242.99 ± 28.56 ***P < 0.005	− 1136.44 ± 35.28 ^#P < 0.05
PA diameter (mm)	2.49 ± 0.20	3.35 ± 0.22 ***P < 0.005	3.14 ± 0.13
ARVd (mm²)	15.13 ± 4.39	12.25 ± 2.42 *P < 0.05	14.83 ± 2.57
ALVd (mm²)	49.18 ± 1.55	40.99 ± 2.75 ***P < 0.005	47.97 ± 1.2 ^###P < 0.005
RVWTd (mm)	0.57 ± 0.06	0.64 ± 0.03	0.63 ± 0.04
PRVOFd (mm)	1.91 ± 0.45	1.93 ± 0.29	2.10 ± 0.20
PRVOFs (mm)	1.56 ± 0.39	1.09 ± 0.31 **P < 0.01	1.53 ± 0.21 ^##P < 0.01
TAPSE (mm)	1.66 ± 0.18	1.25 ± 0.18 *P < 0.05	1.72 ± 0.28 ^##P < 0.01

Velocity Time Integral (VTI, mm); Doppler Peak Velocity (Vel, mm/s); PA diameter (mm); area of the right and left ventricle in diastole (ARVd/ALVd, mm2); right ventricle wall thickness in diastole (RVWTd, mm); proximal ventricle outflow chamber during systole and diastole (PRVOFd, PRVOFs, mm); tricuspid annular plane systolic excursion (TAPSE, mm). Data are shown as the mean ± SD of each experimental group. Five animals from each group were followed
The statistical significance, noticeably different, was represented as ***P < 0.005, **P < 0.01, *P < 0.05 versus control group and ^###P < 0.005, ^##P < 0.01, ^#P < 0.05 versus HH group. The values were calculated by Owo-way ANOVA, Bonferroni post-test

ISSN: 1479-5876